Skip to main content
Heilongjiang ZBD Pharmaceutical Co.,Ltd. logo

Heilongjiang ZBD Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603567 ISIN · CNE100002219 LEI · 300300EKZRUPXURUT924 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,356 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603567

About Heilongjiang ZBD Pharmaceutical Co.,Ltd.

https://www.zbdzy.com/

Heilongjiang ZBD Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of a diverse range of pharmaceutical products. The company focuses on traditional Chinese medicine (TCM), chemical drugs, and biological preparations, with a particular emphasis on treatments for cardiovascular and cerebrovascular diseases. Its product portfolio includes high-tech injections, oral liquids, capsules, and granules. The organization operates large-scale production bases equipped with advanced automation and quality control systems to ensure compliance with international standards. By integrating modern scientific research with traditional medicinal practices, the company aims to provide innovative therapeutic solutions. Its operations span the entire value chain, from raw material cultivation and processing to finished product marketing and sales across domestic and global healthcare sectors.

Recent filings

Filing Released Lang Actions
黑龙江珍宝岛药业股份有限公司关于签订战略合作框架协议的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. regarding the signing of a strategic cooperation framework agreement for drug distribution. It is a compliance/transaction notice between the company (via its subsidiary) and a related party, not a financial report, earnings release, board change, dividend notice, or M&A filing. It is a general regulatory announcement that does not fit any more specific category, making it a fallback Regulatory Filing (RNS).
2026-05-25 Chinese
黑龙江珍宝岛药业股份有限公司第六届董事会第一次会议决议公告
Board/Management Information Classification · 93% confidence The document is a “第六届董事会第一次会议决议公告,” detailing resolutions passed by the board of directors regarding election of the chairman, committee appointments, senior management appointments, stock repurchase and capital reduction, and scheduling of a shareholder meeting. This is a board meeting resolution announcement about board and management changes, fitting the Board/Management Information category.
2026-05-25 Chinese
黑龙江珍宝岛药业股份有限公司关于董事会换届选举及高级管理人员聘任完成的公告
Board/Management Information Classification · 94% confidence The document is a formal corporate announcement detailing the results of the board of directors re-election (sixth board) and the appointment of senior management (general manager, deputy general managers, CFO, board secretary, securities representative). It lists names, positions, terms, committee compositions, and resumes. This fits squarely under Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-05-25 Chinese
黑龙江珍宝岛药业股份有限公司关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 82% confidence The document is a formal notice from Heilongjiang Zhenbaodao Pharmaceutical Co. regarding the board’s resolution to repurchase and cancel 831,995 restricted shares under its 2023 equity incentive plan, with detailed information on repurchase prices and reduction of registered capital. It further notifies creditors of their rights due to the capital reduction. This constitutes a share buyback and cancellation of the company’s own shares, matching the “Transaction in Own Shares” category (POS).
2026-05-25 Chinese
黑龙江珍宝岛药业股份有限公司2025年年度股东会会议资料
AGM Information Classification · 90% confidence The document is the complete meeting materials (notices, agenda, proposals, board reports, annual report summaries, remuneration proposals, board elections, etc.) for the 2025 Annual General Meeting of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. It is not merely an announcement of a report, nor is it the standalone annual report itself; rather, it is the information packet used at the AGM. Therefore, it falls under AGM Information (Code: AGM-R).
2026-05-18 Chinese
黑龙江珍宝岛药业股份有限公司关于无法按期归还暂时用于补充流动资金的募集资金的公告
Capital/Financing Update Classification · 82% confidence The document is an official announcement by Heilongjiang Zhenbaodao Pharmaceuticals about its inability to timely return idle raised funds that were temporarily used to supplement working capital. It details the history of the fundraising, use of proceeds, reasons for delay, and plans to remediate. This is a financing update regarding use and management of capital raised, fitting the Capital/Financing Update category (CAP).
2026-05-13 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.